TY - JOUR
T1 - Venous thromboembolism in the get with the guidelines-stroke acute ischemic stroke population
T2 - Incidence and patterns of prophylaxis
AU - Douds, G. Logan
AU - Hellkamp, Anne S.
AU - Olson, Daiwai M.
AU - Fonarow, Gregg C.
AU - Smith, Eric E.
AU - Schwamm, Lee H.
AU - Cockroft, Kevin M.
N1 - Funding Information:
The Get With The Guidelines–Stroke (GWTG-S) program is currently supported in part by a charitable contribution from Ortho-McNeil . GWTG-S has been funded in the past through support from Boeringher-Ingelheim , Merck , Bristol-Myers Squib/Sanofi Pharmaceutical Partnership , and the American Heart Association Pharmaceutical Roundtable . Sponsors did not participate in the design, analysis, manuscript preparation or approval for this project.
PY - 2014/1
Y1 - 2014/1
N2 - Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolus (PE), represents a serious complication in hospitalized ischemic stroke patients. This study examines the incidence of VTE and the patterns of VTE prophylaxis in acute ischemic stroke patients deemed appropriate for VTE prophylaxis (nonambulatory) in the Get With The Guidelines-Stroke (GWTG-S) study. Methods: We analyzed data from 149,916 patients who were admitted with acute ischemic stroke and enrolled in GWTG-S from 1259 U.S. hospitals. Patient variables and site characteristics were analyzed in relation to reported administration of VTE prophylaxis. Results: The overall rate of VTE prophylaxis in the analysis cohort was 93% (139,476/149,916). The median site prophylaxis rate was 95%, and prophylaxis rates ranged from 17% (1 site) to 100% (101 sites). Factors associated with increased likelihood of VTE prophylaxis in the multivariable model included history of atrial fibrillation/flutter, receipt of intravenous or intra-arterial tissue plasminogen activator, and admission to an academic hospital. Increasing age, black race, and a history of peripheral vascular disease, diabetes, or stroke were associated with lower likelihood of prophylaxis. Patients receiving care in the Midwest were less likely to receive prophylaxis compared to other regions. Conclusions: Despite a high overall rate of VTE prophylaxis, VTE was found to occur in approximately 3% of GWTG-S patients. Reported rates of VTE prophylaxis differed among hospitals by region and hospital type, and among patients by age, race, and medical comorbidities.
AB - Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolus (PE), represents a serious complication in hospitalized ischemic stroke patients. This study examines the incidence of VTE and the patterns of VTE prophylaxis in acute ischemic stroke patients deemed appropriate for VTE prophylaxis (nonambulatory) in the Get With The Guidelines-Stroke (GWTG-S) study. Methods: We analyzed data from 149,916 patients who were admitted with acute ischemic stroke and enrolled in GWTG-S from 1259 U.S. hospitals. Patient variables and site characteristics were analyzed in relation to reported administration of VTE prophylaxis. Results: The overall rate of VTE prophylaxis in the analysis cohort was 93% (139,476/149,916). The median site prophylaxis rate was 95%, and prophylaxis rates ranged from 17% (1 site) to 100% (101 sites). Factors associated with increased likelihood of VTE prophylaxis in the multivariable model included history of atrial fibrillation/flutter, receipt of intravenous or intra-arterial tissue plasminogen activator, and admission to an academic hospital. Increasing age, black race, and a history of peripheral vascular disease, diabetes, or stroke were associated with lower likelihood of prophylaxis. Patients receiving care in the Midwest were less likely to receive prophylaxis compared to other regions. Conclusions: Despite a high overall rate of VTE prophylaxis, VTE was found to occur in approximately 3% of GWTG-S patients. Reported rates of VTE prophylaxis differed among hospitals by region and hospital type, and among patients by age, race, and medical comorbidities.
UR - http://www.scopus.com/inward/record.url?scp=84891791740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891791740&partnerID=8YFLogxK
U2 - 10.1016/j.jstrokecerebrovasdis.2012.10.018
DO - 10.1016/j.jstrokecerebrovasdis.2012.10.018
M3 - Article
C2 - 23253528
AN - SCOPUS:84891791740
SN - 1052-3057
VL - 23
SP - 123
EP - 129
JO - Journal of Stroke and Cerebrovascular Diseases
JF - Journal of Stroke and Cerebrovascular Diseases
IS - 1
ER -